Selected article for: "clinical response and host response"

Author: Chan, Jasper Fuk-Woo; Zhang, Anna Jinxia; Chan, Chris Chung-Sing; Yip, Cyril Chik-Yan; Mak, Winger Wing-Nga; Zhu, Houshun; Poon, Vincent Kwok-Man; Tee, Kah-Meng; Zhu, Zheng; Cai, Jian-Piao; Tsang, Jessica Oi-Ling; Chik, Kenn Ka-Heng; Yin, Feifei; Chan, Kwok-Hung; Kok, Kin-Hang; Jin, Dong-Yan; Au-Yeung, Rex Kwok-Him; Yuen, Kwok-Yung
Title: Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons
  • Document date: 2016_11_12
  • ID: v4r5d26a_3
    Snippet: A number of animal models have been developed for studying the pathogenesis and evaluating countermeasures for ZIKV infection. Rhesus macaques with subcutaneous ZIKV inoculation develop mild clinical signs that resemble the self-limiting illness in most infected immunocompetent adults (Dudley et al., 2016) . This non-human primate model provides a robust platform for the evaluation of vaccines and host immune response (Abbink et al., 2016) . Howe.....
    Document: A number of animal models have been developed for studying the pathogenesis and evaluating countermeasures for ZIKV infection. Rhesus macaques with subcutaneous ZIKV inoculation develop mild clinical signs that resemble the self-limiting illness in most infected immunocompetent adults (Dudley et al., 2016) . This non-human primate model provides a robust platform for the evaluation of vaccines and host immune response (Abbink et al., 2016) . However, the mild clinical disease in these primates is suboptimal for antiviral treatment evaluation. Moreover, expertise and facilities for working with non-human primates are not available in most research laboratories. Wild-type adult BALB/c mice are not susceptible to intraperitoneal ZIKV inoculation (Dick, 1952) . Suckling and young mice with intracerebral ZIKV inoculation develop disease that is localized to the central nervous system (Dick, 1952; Way et al., 1976; Weinbren and Williams, 1958; Bell et al., 1971) . Pregnant mice and fetal mice with partially intact type I interferon signaling response (fetuses of female mice deficienct in type I interferon signaling response crossed to wild-type male mice) were used to study pathogenesis in pregnancy and maternalfetal transmission, but these models are technically more demanding (Miner et al., 2016; Cugola et al., 2016) . Type I/II interferon-signaling-/ receptor-deficient mice with intraperitoneal or subcutaneous ZIKV inoculation develop fatal, disseminated infection (Lazear et al., 2016; Dowall et al., 2016; Aliota et al., 2016; Rossi et al., 2016) . These models are useful for the evaluation of countermeasures for ZIKV infection as the protective effects of antivirals drugs and vaccines are more easily observed in treated mice. However, such models have complete/nearcomplete deficiency in interferon response and do not resemble the real clinical situation in immunosuppressed humans. Moreover, these mice are suboptimal for the study of host immune response and may be too expensive for laboratories in resource-limited areas.

    Search related documents:
    Co phrase search for related documents
    • animal model and antiviral treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • animal model and central nervous system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • animal model and clinical disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • animal model and clinical sign: 1
    • animal model and clinical situation: 1, 2
    • antiviral drug and central nervous system: 1, 2, 3, 4, 5
    • antiviral drug and clinical disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral drug and clinical situation: 1, 2
    • antiviral treatment and central nervous system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • antiviral treatment and clinical disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral treatment and clinical sign: 1
    • antiviral treatment and clinical situation: 1, 2
    • antiviral treatment and disseminate infection: 1
    • central nervous system and clinical disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • central nervous system and clinical sign: 1, 2
    • central nervous system and disseminate infection: 1, 2
    • central nervous system and female mouse: 1